Background
==========

Acute coronary syndromes (*ACS*) are a manifestation of ischemic heart disease with high morbidity and are a leading cause of mortality in industrialized countries \[[@b1-medscimonit-21-171],[@b2-medscimonit-21-171]\]. According to the universal definition of myocardial Infarction, elevated cardiac troponin is one of the key diagnostic components for the diagnosis of acute myocardial infarction (*AMI*) \[[@b3-medscimonit-21-171]\]. High-sensitivity troponin T (*hs-TnT*) assay does not provide information on the mechanism of cell damage despite its high sensitivity in the detection of myocardial necrosis. Accordingly, patients with chest pain, elevated markers of myocardial cell damage, and ECG changes are typically referred to invasive coronary angiography. However, a proportion of coronary angiograms, ranging from 4% to 7%, are revealed to be culprit-free, angiographically normal, epicardial coronary arteries \[[@b4-medscimonit-21-171],[@b5-medscimonit-21-171]\]. Acute chest pain in non-acute coronary syndrome (*non-ACS*) patients may be the clinical manifestation of a variety of pathologies, including myocarditis, pulmonary or coronary artery embolism, stress cardiomyopathy (*Takotsubo cardiomyopathy*, *TTC*), and myocardial ischemia originating from microvascular dysfunction*.* In these patients the prognosis can range from benign to the development of severe heart failure. Therefore, an accurate diagnosis in this group is crucial to achieve accurate risk stratification and to choose the best treatment strategy. Cardiac magnetic resonance (*CMR*) has been shown to be ideally suited for myocardial tissue characterization and is able to detect and differentiate pathologic changes at the level of myocardium \[[@b6-medscimonit-21-171],[@b7-medscimonit-21-171]\]. However, CMR is of limited availability across Europe.

The present study aimed at the evaluation of the additional value of CMR over commonly available non-CMR standard tests, including hs-TnT assay, for the differentiation of myocardial injury in patients with ACS and non-obstructed coronary arteries.

Material and Methods
====================

Study protocol
--------------

Patients admitted with an initial diagnosis of ACS and having normal coronary arteries at coronary angiogram were prospectively enrolled in this multicenter, observational study. Enrollment was performed in 2 tertiary cardiology centers, the 2^nd^ Department of Cardiology, Zabrze, Silesian Medical University of Katowice (*SUM*), Poland and the Department of Cardiology, Centre Hospitalier Universitaire Vaudois (*CHUV*), Lausanne, Switzerland between January 2009 and July 2013. The study did not require the approval of the local Ethics Committee.

Inclusion criteria were: 1) acute retrosternal chest pain during the last 24 h, 2) elevated hs-TnT level (\>14 ng/l) at admission or after 6 h, and 3) nonsignificant coronary stenosis on coronary angiogram (stenosis \<30%) as analyzed by 2 independent invasive cardiologists. Exclusion criteria were: 1) history of coronary revascularization, 2) past myocardial infarction, 3) hypertensive heart disease, 4) tachyarrhythmia, 5) peripheral artery disease, 6) history of stroke, 7) coronary vasospasm, 8) renal insufficiency (creatinine \>200μmol/l), and 9) recent septicemia.

During hospitalization a clinical examination, ECG, and echocardiography were obtained for every patient. Baseline blood samples were analyzed for full blood count, C-reactive protein (*CRP*), hs-TnT, creatine kinase myocardial bound (*CK-MB*), and lipid profile. The measurement of hs-TnT was conducted on the Cobas e 411 immunoanalyzer, which is based on electrochemiluminescence technology (with detection limit of 3--10000 ng/l, 99^th^ percentile level of 14 ng/l, and 10% coefficient of variation level of 13 ng/l) according to the manufacturer instructions (Roche Diagnostics, Mannheim Germany).

All patients were referred to the hospital with a suspicion of AMI and underwent an initial work-up with past medical history, current symptoms, clinical, electrocardiographic and echocardiographic examination, hs-TnT level, and coronary angiogram. Baseline left ventricular ejection fraction (*LVEF*) was measured with echocardiography. The infection was defined as symptoms of recent (\<14 days) respiratory or gastro-intestinal infection with or without fever. After exclusion of AMI with a culprit-free coronary angiogram, patients were reclassified and referred for CMR with a suspicion of either TTC (based on Mayo Clinic criteria \[[@b8-medscimonit-21-171]\]) or myocarditis (based on European Society of Cardiology position statement \[[@b9-medscimonit-21-171]\]). All procedures were conducted according to current clinical standards of care and no additional consent was obtained regarding ethical concerns. Final diagnosis was based on the distribution pattern of myocardial injury as identified by the late gadolinium enhancement (*LGE*) in CMR.

Cardiac magnetic resonance
--------------------------

CMR studies were performed using a GE Signa MR scanner (SUM, Poland), a Siemens Magnetom Symphony (until 2009), or a Magnetom Aera (starting in 2009) MR scanner (CHUV, Switzerland). The CMR protocol included sequences for left ventricular (LV) volumes, function, and mass. LV function and mass were assessed using a stack of standard ECG-gated, steady-state, free precession (SSFP), short axis images covering the LV from base to apex. Recommended major diagnostic CMR criteria for myocarditis were primarily based on the findings on LGE, a marker of incomplete washout of contrast medium from myocardium, late after the injection (10--20 min after the intravenous administration of conventional extracellular gadolinium chelate at a dose of 0.15--0.2 mmol/kg) \[[@b10-medscimonit-21-171],[@b11-medscimonit-21-171]\]. In a subset of patients (see below), edema-sensitive T~2~-weighted images (T~2~-ratio) (using a triple inversion-recovery sequence with inversion pulses, including blood flow and fat suppression) and global T~1~ enhancement (early gadolinium enhancement \[EGE\] obtained from spin echo imaging techniques and defined as an increased normalized uptake of gadolinium chelate early \[\~3 min\] after its intravenous administration) were also assessed \[[@b1-medscimonit-21-171],[@b12-medscimonit-21-171]\]. To efficiently null the signal of viable myocardium, the optimal inversion time was adjusted. Abnormalities were analyzed from short axis view, 2-, 3-, and 4-chamber views, and localized based on the American Heart Association 17-segment model \[[@b13-medscimonit-21-171]\]. AMI was diagnosed if subendocardial signal enhancement in the distribution of a coronary artery was detected on LGE sequences (with or without a corresponding positive finding on T~2~-weighted images and/or MVO) ([Figure 1](#f1-medscimonit-21-171){ref-type="fig"}). Myocarditis was diagnosed if subepicardial and/or patchy LGE lesions were detected in the LV myocardium according to previously published studies \[[@b10-medscimonit-21-171],[@b11-medscimonit-21-171]\] ([Figure 2](#f2-medscimonit-21-171){ref-type="fig"}). When scan logistics were favorable, T~2~-weighted and T~1~-weighted sequences were also acquired to calculate T~2~-ratio and T~1~-global enhancement as described elsewhere (n=24, SUM, Poland). CMR was considered normal if there were no LGE, MVO, or T~2~ intensity abnormalities, and if left and right ventricular function were normal. In the patients with suspected TTC (based on normal coronary arteries in coronary angiogram and typical wall motion abnormalities on baseline echocardiography), the diagnosis of TTC was maintained after the CMR study, if myocarditis and typical infarct pattern in LGE was excluded by CMR, even when regional wall motion abnormalities were no longer present.

Outcomes
--------

Patients were followed up at 30 days and 6 months. Data at 30 days were obtained by phone calls or were retrieved from medical records. Data at 6 months were gathered during a control visit in the outpatient unit, which included basic physical examination, echocardiographic examination, and a review of medical treatment.

A combined clinical end-point included death of cardiovascular origin, non-fatal AMI, heart failure (*de novo* according to Framingham criteria \[[@b14-medscimonit-21-171]\] or decompensation of existing heart failure), and electrocardiographically documented ventricular tachyarrhythmia.

Statistical analysis
--------------------

Values are presented as means ±standard deviation or median (25^th^; 75^th^ percentile) as appropriate. The comparison of variables between groups was performed using t-test or Mann-Whitney U test and Kruskal-Wallis test for continuous variables and chi-square test for categorical variables. A p value \<0.05 was considered statistically significant. All analyses were performed using Statistica software, version 9PL (StatSoft Inc., Tulsa, OK, USA) and GraphPad Prism software version 6.00 (GraphPad, La Jolla, California, USA).

Results
=======

From January 2009 to July 2013, 5110 patients were admitted to the Emergency Departments with chest pain and were identified with elevated levels of cardiac biomarkers. Of these, 75 patients (1.5%) had a normal coronary angiogram and were eligible for the study.

Population characteristics
--------------------------

The mean age was 40.0±14.6 years, 31 patients (79%) were male, and 21 patients (28%) presented with a recent history of infection. Baseline clinical characteristics are summarized in [Table 1](#t1-medscimonit-21-171){ref-type="table"}.

Initial evaluation
------------------

After initial clinical assessment using standard tests and provisional exclusion of AMI by coronary angiogram, 69 patients (92%) had suspected myocarditis and 6 patients (8%) had suspected TTC ([Figure 3](#f3-medscimonit-21-171){ref-type="fig"}). Patients in these 2 diagnostic categories did not differ regarding cardiovascular risk factors or baseline ECG. Patients in the TTC group were older (p=0.03) and all were female (p\<0.001). Median LVEF was lower for TTC patients than in myocarditis patients (48% *vs.* 59%, respectively, p\<0.001). No differences were found regarding wall motion abnormalities (*WMA*), chamber diameters, or pericardial effusion. The biomarkers of myocardial necrosis for the total cohort were elevated but did not differ between groups (p=0.67 for hs-TnT, p=0.51 for CK-MB). In patients in the TTC group, lower values of erythrocytes count, hemoglobin and hematocrit and higher values of high-density lipoprotein (*HDL*) were observed ([Table 1](#t1-medscimonit-21-171){ref-type="table"}).

Cardiac magnetic resonance
--------------------------

CMR was performed in all 75 patients, with a mean delay of 12.8 days after the onset of cardiac symptoms. CMR showed diagnostic changes in 79% of cases (59 patients) and was normal in 21% (16 patients) ([Figure 3](#f3-medscimonit-21-171){ref-type="fig"}).

Out of the 16 patients with negative LGE findings, in 6 patients T~2~-ratio and T~1~ global enhancement were also determined. In only 1 patient out of those (1/6 patients), a borderline positive T~1~ global enhancement of 3.4 was found (normal \<2.9 \[[@b15-medscimonit-21-171]\]), while the T~2~ ratio of 1.3 was also within normal limits (normal \<2.0 \[[@b11-medscimonit-21-171],[@b16-medscimonit-21-171]\]). Therefore, this patient was categorized as normal, i.e. non-injured myocardium as assessed by LGE (= myocarditis negative). Out of the 49 patients with LGE findings positive for myocarditis, in 18 patients T~2~-ratio and T~1~ global enhancement were also determined. Out of these 18 LGE-positive patients, T~2~-ratio and T~1~ global enhancement were positive in 8 and 7 patients, respectively.

In the patients included into the study (i.e., patients with acute chest pain, elevated markers of myocardial necrosis, and normal coronary arteries), the diagnosis of the standard diagnostic tests (clinical examination, ECG, echocardiography, biomarkers, and coronary angiogram) was correct in only 66% of patients (50 patients) based on the final results provided by CMR as the gold standard (47 out of 69 suspected and 3 TTC out of 6 suspected). With the initial assessment, the final diagnosis was missed in 25 patients (33%). Specifically, the diagnosis was changed in 9 patients (12%), and suspected myocardial disease was excluded in another 16 patients (21%). Out of 69 patients with initially suspected myocarditis, the diagnosis was confirmed in 47 patients (68%), reclassified to AMI in 6 patients (9%) and to non-injured myocardium in 16 patients (23%). Among 6 patients with suspected TTC, the diagnosis was confirmed in 3 (50%), reclassified to myocarditis in 2 (33%), and to AMI in 1 (17%).

In summary, the final diagnosis after CMR was unrecognized AMI in 7 patients (9%), myocarditis in 49 patients (65%), TTC in 3 patients (4%), and non-injured myocardium in 16 patients (21%) ([Figure 3](#f3-medscimonit-21-171){ref-type="fig"}). No differences in ECG, echocardiographic characteristics, and biomarkers were found between those groups ([Table 2](#t2-medscimonit-21-171){ref-type="table"}). Groups differed regarding age (older patients in the TTC group and younger patients in the myocarditis group, p=0.002) and sex (with 86% of males in the myocarditis group and no males in the TTC group, p\<0.001).

Outcomes
--------

No clinical endpoints were reported for the 30-day and 6-month follow-up. At the 6-month follow-up, no significant echocardiographic changes were observed when compared with the initial examination. The median change in LVEF as assessed by echocardiography was -- 2% (range -- 22;20) for the total population and -- 3% (range -- 22;20), -- 1% (range -- 16;8) and -- 4% (range -- 3;7) for the myocarditis, AMI, and non-injured myocardium group, respectively, p=0.91.

Discussion
==========

Patients with chest pain, elevated troponin, and normal coronary arteries constitute a heterogeneous group with unclear prognosis \[[@b17-medscimonit-21-171]\]. In several studies these patients had similar or even worse prognosis than patients with AMI receiving revascularization therapy \[[@b18-medscimonit-21-171]--[@b20-medscimonit-21-171]\] whereas other authors reported an evolution without adverse events \[[@b21-medscimonit-21-171],[@b22-medscimonit-21-171]\]. Establishing the correct diagnosis is therefore crucial to ensure that patients are correctly risk-stratified and receive adequate treatment.

Our data suggest that the standard diagnostic workup with ECG, biomarkers, and echocardiography is insufficient in this setting, and that a large proportion of patients presenting with acute coronary syndrome, elevated troponin, and normal coronary angiogram have probable myocarditis \[[@b23-medscimonit-21-171]\]. The sensitivity of CMR to detect myocarditis ranges from 60% to 90% \[[@b24-medscimonit-21-171]--[@b26-medscimonit-21-171]\], depending on localization of the pathological process and LGE in the myocardium, the CMR sequence used, wall thickness, the challenging comparison between histological segments with CMR locations, the technique of histopathological analysis used, and patient selection. Endomyocardial biopsy is the gold standard test to diagnose myocarditis, with a recent position paper of the ESC favoring the systematic use of endomyocardial biopsy in this particular setting \[[@b9-medscimonit-21-171],[@b27-medscimonit-21-171]\], but its use is currently restricted to specific clinical situations \[[@b28-medscimonit-21-171]\] because of its invasive nature and the potential complications associated with this procedure.

In the present study, CMR was performed according to the current recommendations \[[@b7-medscimonit-21-171],[@b11-medscimonit-21-171]\]. The enrollment criteria were consistent with appropriate indications for CMR imaging. In the cohort, 65% of patients received the final diagnosis of myocarditis and 9% of the study population was diagnosed with unrecognized AMI. This is in contrast to previous data in which CMR yielded a higher rate of AMI in patients with ACS presentation and culprit-free coronary angiogram \[[@b29-medscimonit-21-171]\], but it is in line with other reports showing that most patients admitted with chest pain, high troponin, and normal coronary angiogram were finally diagnosed with myocarditis \[[@b30-medscimonit-21-171]\]. Of notice, the diagnosis of myocarditis was based on LGE assessment only in the majority of cases with 32% ratio of co-evaluation with T~1~ global enhancement and T~2~-ratio, which should be mentioned in the context of assessing the rate of myocarditis/AMI in the studied population.

One might have expected to find a higher proportion of ischemia-induced myocardial damage (LGE positive areas) with CMR in the population diagnosed with elevated hs-TnT as the marker for myocardial damage. Previous studies reported a higher incidence of myocardial necrosis despite the absence of significant (\>30%) epicardial coronary stenosis \[[@b31-medscimonit-21-171]\]. However, these studies also included patients with minimal atheromatosis in coronary angiogram and a positive history of coronary artery disease (*CAD).* Conversely, in our cohort, patients with a positive history of CAD were excluded and the majority of patients had completely smooth coronary arteries in angiography ([Figure 4](#f4-medscimonit-21-171){ref-type="fig"}) with no case showing diffuse CAD (mild pathological changes were found in only 8 patients). This is reflected in the low (1.5%) incidence of fulfilling the criteria for culprit-free angiograms. Thus, in the earlier studies CAD was more advanced than in our study, most likely explaining the lower incidence of necrotic lesions detected by CMR in our study. Out of the 8 patients with mild pathological changes in the coronary angiogram, 1 was diagnosed with AMI. A retrospective analysis of the angiogram in this patient with AMI revealed an occluded thin diagonal branch (\<1 mm), which was missed at first, possibly responsible for the localized transmural zone of LGE on CMR.

Early performance of CMR in patients with suspected myocarditis has been proposed \[[@b32-medscimonit-21-171]\]. Some authors suggest that CMR could be chosen even before coronary angiography as the primary investigation if supported by relevant clinical findings \[[@b33-medscimonit-21-171],[@b34-medscimonit-21-171]\]. Others raised the problem of cardiovascular risk underestimation \[[@b35-medscimonit-21-171]\] and demonstrated that the incidence of AMI in young adults is not marginal \[[@b34-medscimonit-21-171]\]. In the present population, young patients (\<40 years old) constituted 55% of the myocarditis group and 14% of the AMI group (median 58 *vs.* 37 years, respectively, p=0.02). Although young patients are being diagnosed with myocarditis 4 times more frequently than older patients, their 14% contribution to the AMI group is important. Therefore, also in young patients, CMR should not be preferred over coronary angiography, with the latter remaining the diagnostic method of choice for a definite exclusion of CAD in the setting of acute chest pain.

Considering the relatively weak diagnostic yield of standard tests, CMR should be strongly advised in cases of acute chest pain, elevated troponin, and normal coronary arteries. The real-world circumstances limit the possibilities of its introduction into clinical practice. The study hypothesis was built and driven by a threatening diversity in the statistics of CMR utilization across Europe. It is known that in Western European regions, CMR has a utilization rate of 13% \[[@b36-medscimonit-21-171]\] and the regional diversity in CMR availability is important. In Switzerland, a single university hospital (CHUV, Lausanne) reports approximately 1500 exams per year (per \~0.5--1 million inhabitants), while an annual rate of 250 CMR examinations is reported in the Silesian region of Poland for a population of over 4.6 million inhabitants (data from the Silesian Department of the National Health Insurance Service, 2013). And finally, in Romania, CMR is still rarely available in some regions (e.g., no CMR was available until 2013 in Jassy, with a population of \>300 000). In the era of minimizing invasive diagnostic procedures and the tendency to perform evidence-based medicine, CMR emerges as the most appropriate diagnostic method, counterbalancing the financial, social, and personal costs of a misdiagnosed patient.

Limitations
-----------

The number of enrolled patients was rather low and was not sufficient to achieve statistical significance for the comparison of a large number of variables between groups. Although included patients mainly had smooth coronary arteries on coronary angiography, the lack of routine application of intravascular ultrasound or coronary optical coherence tomography has to be mentioned. Due to independent technical conditions, the time window of CMR was broad and the results provided could led to under-diagnosis of the characteristic transient pattern of TTC or lower frequency of abnormalities indicative of myocarditis (edema and LGE).

Conclusions
===========

The study results suggest the high diagnostic yield of CMR in patients with an acute coronary syndrome and a culprit-free angiogram. The diagnostic performance of commonly available non-CMR-based tests in this setting is insufficient and leads to a 9% missed diagnosis of AMI if not verified by CMR. The evaluation of patients with chest pain, elevated troponin, and normal coronary arteries should be complemented by a CMR examination if available.

**Conflict of interests**

The authors declare that they have no conflict of interests.

**Source of support:** Departmental sources

![Cardiac magnetic resonance -- myocardial infarction. A -- Localized, transmural zone of late gadolinium enhancement (*LGE*) within lateral wall (**A**) and apex (**D**) in short axis view (*SAX*) and 4-chamber (**E**) and 2-chamber (**F**) view (arrows). Cine MR images in SAX (**B** -- diastole, **C** -- systole) demonstrate corresponding wall motion abnormalities of the lateral wall (arrows in **B** and **C**).](medscimonit-21-171-g001){#f1-medscimonit-21-171}

![Cardiac magnetic resonance -- myocarditis. Typical subepicardial and patchy zones of late gadolinium enhancement (*LGE*) in short axis (*SAX*) (**A**), 2-chamber (**C**) and 3-chamber (**D**) views (arrows) with a corresponding SAX cine image (**B**).](medscimonit-21-171-g002){#f2-medscimonit-21-171}

![The evolution of the diagnosis. CMR -- cardiac magnetic resonance.](medscimonit-21-171-g003){#f3-medscimonit-21-171}

![Coronary angiogram. Angiograms showing smooth coronary arteries in a patient finally diagnosed with myocardial infarction (**A, B**), with Takotsubo cardiomyopathy (**C, D**), and aneurismal coronary arteries in a patient finally diagnosed with myocarditis (**E, F**). Final diagnosis was established according to the result of cardiac magnetic resonance. LCA -- left coronary artery, RCA -- right coronary artery.](medscimonit-21-171-g004){#f4-medscimonit-21-171}

###### 

Characteristics of the population and subgroups according to the initial diagnosis.

  Characteristics                                   Total population n=75   Myocarditis n=69     Takotsubo n=6         p value[\*](#tfn2-medscimonit-21-171){ref-type="table-fn"}
  ------------------------------------------------- ----------------------- -------------------- --------------------- ------------------------------------------------------------
  Clinical                                                                                                             
  Age (years)                                       44.9±16.2               43.6±15.8            59±14.2               0.03
  Male                                              54 (72)                 54 (72)              0 (0)                 \<0.001
  BMI (kg/m^2^)                                     26.9 (24.5; 30.1)       27.1 (24.6; 30.4)    21.9 (20.3; 28.4)     0.12
  Familial history of coronary artery disease (%)   11 (15)                 11 (16)              0 (0)                 0.58
  Hypertension (%)                                  22 (29)                 21 (30)              1 (17)                0.66
  Dyslipidemia (%)                                  16 (21)                 14 (20)              2 (33)                0.60
  Diabetes (%)                                      5 (7)                   4 (6)                1 (17)                0.35
  Current smoking (%)                               25 (3)                  23 (33)              2 (33)                \>0.9
  Former smoking (%) (\>1 year abstinence)          11 (15)                 11 (16)              0 (0)                 0.58
  Recent infection (%)                              23 (31)                 23 (33)              0 (0)                 0.17
  **Laboratory**                                                                                                       
  NT-proBNP (pg/ml)                                 233.3 (95.3;693)        229.3 (88.7;593.3)   3905                  --
  C-reactive protein (mg/l)                         10 (5;28.5)             10 (5;29.9)          6 (2.8; 9.3)          0.27
  Peak creatine kinase -- MB (IU/l)                 47 (30.5;93)            49 (31,99)           44 (26;62)            0.51
  Peak hs-TnT (ng/ml)                               527.6 (139.8;3024)      650.8 (108.2;3060)   464.5 (365;2998)      0.67
  Leukocytes (g/l)                                  9.4 (6.7; 11.7)         9.4 (6.8;11.7)       8.6 (6.5; 14.7)       0.82
  Erythrocytes (g/l)                                4.89 (4.68;5.2)         4.9 (4.72; 5.2)      4.48 (4.29; 4.76)     0.004
  Hemoglobin (g/l)                                  148 (139; 153)          150 (140; 154)       135 (128; 142)        0.005
  Hematocrite (%)                                   44 (41.6; 46.6)         44 (42; 46.7)        40.8 (38.8; 43.1)     0.02
  Platelets (g/l)                                   231 (195.5;270.8)       230.5 (196;265.8)    304.5 (184.4;340)     0.14
  Na (mmol/l)                                       139 (136;142)           139 (136;142)        140.5 (135.5;142.3)   0.76
  Cholesterol total (mg/dl)                         173 (139; 212)          172 (139; 207.5)     226 (110.8;270.5)     0.21
  HDL (mg/dl)                                       47 (35;60.4)            46 (34.8; 58)        131 (59.9; 136.7)     0.008
  Triglycerides (mg/dl)                             91.5 (63.5;131.5)       93 (67;133)          64 (35; 112)          0.23
  LDL (mg/dl)                                       102.1 (77.2;131.1)      101.8 (71.8;130)     104.9 (85; 217.3)     0.48
  **Echocardiogram transthoracic**                                                                                     
  Left ventricular ejection fraction (%)            57 (50; 60)             59 (50; 60)          48 (23.6; 49.2)       \<0.001
  LVEDV (ml)                                        96 (78; 110)            99 (78; 111.5)       87 (73.3; 92.5)       0.2
  LVESV (ml)                                        44.5 (28.5; 50)         44 (27.5; 52)        45 (35; 48)           0.9
  Wall motion abnormalities                         29 (39)                 25 (36)              4 (67)                0.16
  Pericardial effusion                              13 (17)                 13 (19)              0 (0)                 0.37
  Cardiac arrest/shock                              0 (0)                   0 (0)                0 (0)                 --

Data are presented as mean ±SD, median (25^th^; 75^th^ percentile) or n (%);

between the myocarditis group and TTC group.

###### 

Clinical characteristics of the population and subgroups based on CMR result.

  Characteristics                                   Myocarditis n=49     Ischemia n=7         TTC n=3            Non-injured myocardium n=16   p value[\*](#tfn4-medscimonit-21-171){ref-type="table-fn"}
  ------------------------------------------------- -------------------- -------------------- ------------------ ----------------------------- ------------------------------------------------------------
  **Clinical**                                                                                                                                 
  Age (years)                                       37 (28; 51)          58 (50;61)           66 (54; 82)        52.5 (40.5;65.8)              0.002
  Male (%)                                          42 (86)              2 (28)               0 (0)              10 (63)                       \<0.001
  BMI (kg/m^2^)                                     26.8 (24.8;30.2)     28.3 (19.9;39.8)     21.2 (20.4;21.9)   27.8 (24.6;29.9)              0.27
  Familial history of coronary artery disease (%)   7 (14)               0 (0)                0 (0)              4 (25)                        0.39
  Hypertension (%)                                  13 (27)              3 (43)               0 (0)              6 (38)                        0.49
  Dyslipidemia (%)                                  10 (20)              1 (14)               0 (0)              5 (31)                        0.59
  Diabetes (%)                                      2 (4)                1 (14)               1 (33)             1 (6)                         0.22
  Current smoking (%)                               18 (37)              3 (43)               1 (33)             3 (19)                        0.54
  Former smoking (%) (1 year abstinence)            6 (12)               0 (0)                0 (0)              5 (31)                        0.15
  Recent infection (%)                              17 (35)              0 (0)                0 (0)              6 (38)                        0.16
  **Laboratory**                                                                                                                               
  NT-proBNP (pg/ml)                                 233.7 (151;332.4)    821.4 (79.8;1563)    \-                 224.8 (22.4;1083)             --
  C-reactive protein (mg/l)                         10 (5; 32)           20.4 (4; 60.2)       7 (7;7)            5.8 (4.3;16.4)                0.51
  Peak creatin kinase - MB (IU/l)                   50 (34; 103)         59 (21; 77)          35.5 (24; 47)      34 (24;88)                    0.47
  Peak hs-TnT (ng/ml)                               774.3 (258.8;3091)   1850 (410;7180)      700 (449;9890)     165 (40.6;811.1)              0.09
  Leukocytes (g/l)                                  9.8 (6.7;11.7)       10.7 (6; 11.9)       9.7 (7.5;14.3)     8.8 (7; 9.9)                  0.84
  Erythrocytes (g/l)                                4.9 (4.8; 5.2)       4.7 (4.3; 5.0)       4.3 (4.2; 4.8)     4.8 (4.5; 5.1)                0.03
  Hemoglobin (g/l)                                  150 (143;154)        147 (129;154)        133 (125;140)      144 (136;152)                 0.02
  Hematocrite (%)                                   44.4 (42;46.9)       44 (40; 45.6)        39 (38; 42)        43 (40.5;46.6)                0.05
  Platelets (g/l)                                   230 (196;265.8)      231 (170;269)        336 (185;352)      243 (197.5;283.8)             0.63
  Na (mmol/l)                                       139 (136;142)        141 (136;143)        141.1 (140;142)    139 (137;142)                 0.57
  Cholesterol total (mg/dl)                         163.5 (129;204.8)    208 (111;216)        224 (146;228)      197 (158;212)                 0.42
  HDL (mg/dl)                                       46 (34; 57.5)        44 (35.6;70.3)       131                54 (39.5;69.5)                0.28
  Triglycerides (mg/dl)                             85.5 (69.5;118.3)    88.5 (49.8;119.8)    35                 138 (44; 220)                 0.44
  LDL (mg/dl)                                       102.1 (69.3;135)     109.5 (71.1;131.6)   85                 110.8 (75.4;128.1)            0.980
  **Echocardiogram transthoracic**                                                                                                             
  Left ventricular ejection fraction (%)            58 (50; 60)          60 (55; 60)          25 (20; 50)        55 (54; 60)                   0.06
  LVEDV (ml)                                        90 (90; 93)          97.5 (75.5;110)      83 (83; 83)        110 (78; 120)                 --
  LVESV (ml)                                        37.5 (27; 50)        52 (48; 56)          45 (45; 45)        50 (46; 56)                   --
  Wall motion abnormalities                         20 (41)              4 (57)               2 (67)             3 (19)                        0.14
  Pericardial effusion (%)                          10 (20)              0 (0)                0 (0)              3 (19)                        0.49
  Cardiac arrest/shock                              0                    0                    0                  0                             --

Data are presented as mean ±SD, median (25^th^; 75^th^ percentile) or n (%);

between all groups.
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